RxNews Recap for Monday 11-30-09 Print E-mail
By Mary Davila   
Monday, 30 November 2009 18:22
Below is a list of the companies that made news in the healthcare sector on Monday, November 30, 2009.



Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.


Cell Therapeutics, Inc. (CTI) (Nasdaq:CTIC) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (NYSE:SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone - 400mg Tablets) in all 27 European member states.

Cypress Bioscience, Inc. (NASDAQ:CYPB) today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009.

Clarient, Inc. (Nasdaq:CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, announced that it had been selected to the Deloitte Technology Fast 50 China 2009 list for the fifth consecutive year.

Exiqon A/S (NASDAQ:OMX) announced today that the Harvard Medical School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence.ICCB-L supports investigators at Harvard Medical School, and associated hospitals and institutions, for high-throughput screening of small molecule and RNAi libraries.

NanoViricides, Inc. (OTCBB:NNVC.OB) (the "Company"), reports that the Company has filed its quarterly report with the SEC on November 23rd.

Gentium S.p.A. (NASDAQ:GENT) (the “Company”) today reported financial results for the quarter ended September 30, 2009.

Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Oxygen Therapy assets to Chart Industries, Inc. (NASDAQ:GTLS). Financial terms of the transaction were not disclosed.

Spectrum Pharmaceuticals (NasdaqGM:SPPI) today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer.

Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

Emisphere Technologies, Inc. (OTCBB:EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to extend the maturity date of Emisphere’s Convertible Promissory Note (the “Note”) to February 26, 2010.

Cannabis Science Inc. (OTCBB:CBIS) an emerging pharmaceutical cannabis company, is honored to announce that Dr. Ben Johnson, Dr. Allan Shackleford and Dr. William Courtney have accepted its request to become members of its recently formed Scientific Advisory Board.

Tongjitang Chinese Medicines Company (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it will hold its annual general meeting of shareholders for the fiscal year ended December 31, 2009 at the Company’s executive office on 5th Floor, Block B, Nanshan Medical Device Park, 1019 Nanhai Avenue, Nanshan District, Shenzhen, 518067 Guangdong Province, People’s Republic of China on December 23, 2009 at 11 a.m. (local time).

Sunshine Biopharma, Inc., (OTCBB: MWBN) today announced that the trading symbol for its common stock has changed to “SBFM”effective immediately.

PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has solidified plans to expand its retail product line with the addition of spirulla.

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology.

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has commenced an underwritten public offering of up to 12,500,000 shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of the Company’s common stock.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter